The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However, the recent emergence of the Omicron variant has posed a challenge, as it evades detection by most existing SARS-CoV-2 neutralizing antibodies (nAbs). Here, we successfully generated a panel of SARS-CoV-2/SARS-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Hualong, Sun, Hui, Wang, Siling, Yuan, Lunzhi, Liu, Liqin, Zhu, Yuhe, Zhang, Jinlei, Huang, Yang, Qi, Ruoyao, Jiang, Yao, Ma, Jian, Zhou, Ming, Ma, Yue, Fu, Rao, Yan, Siping, Yue, Mingxi, Wu, Yangtao, Wei, Min, Wang, Yizhen, Li, Tingting, Wang, Yingbin, Zheng, Zizheng, Yu, Hai, Cheng, Tong, Li, Shaowei, Yuan, Quan, Zhang, Jun, Guan, Yi, Zheng, Qingbing, Zhang, Tianying, Xia, Ningshao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407403/
https://www.ncbi.nlm.nih.gov/pubmed/35972965
http://dx.doi.org/10.1073/pnas.2204256119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407403/
https://www.ncbi.nlm.nih.gov/pubmed/35972965
http://dx.doi.org/10.1073/pnas.2204256119

Ejemplares similares